Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05363891 · ClinicalTrials.gov registry record · Phase 2
Natrunix or Placebo in Combination With Methotrexate in Rheumatoid Arthritis
A Phase 2 study, sponsored by XBiotech.
- Completed
- Registry status
- Phase 2
- Development phase
- 243
- Enrollment target
NCT05363891: Completed Phase 2 study, sponsored by XBiotech.
NCT05363891 is a Phase 2 study that has completed, run by XBiotech. The registered enrollment target is 243 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (83% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05363891, a Phase 2 study, has completed, sponsored by XBiotech.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 243 participants
- Enrollment target
Study Summary
Phase II, Double-Blind, Placebo-Controlled, Randomized Trial Examining Natrunix in Combination with MTX (+Folate) for the Treatment of Rheumatoid Arthritis
Primary Outcome
The ACR is a measure used in clinical practice and clinical trial to assess medication efficacy in patients with RA, by notating improvements in swelling and tenderness in designated joints, as well as improvements in at least 3 out of 5 other categories. The other categories assessed are patient global assessment of disease activity, physician global assessment of disease activity, patient reported pain scale, disability/functionality questionnaire response, and acute phase reactant levels (CRP
Interventions
- DRUG Placebo
- DRUG Natrunix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 243 participants |
| Start Date | 2023-08-08 |
| Est. Completion | 2024-10-31 |
| Phase | Phase 2 |
What the finished NCT05363891 record still lists
NCT05363891 is an interventional study that assigns participants to a tested intervention. The registered 243 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (83% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05363891 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05363891 about?
NCT05363891 is a clinical study titled "Natrunix or Placebo in Combination With Methotrexate in Rheumatoid Arthritis". Phase II, Double-Blind, Placebo-Controlled, Randomized Trial Examining Natrunix in Combination with MTX (+Folate) for the Treatment of Rheumatoid Arthritis
What is the current status of trial NCT05363891?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 243 participants. The study started on 2023-08-08. Estimated completion is 2024-10-31.
What interventions are being tested in trial NCT05363891?
The interventions under investigation include: Placebo (DRUG), Natrunix (DRUG).
Who is sponsoring clinical trial NCT05363891?
This trial is sponsored by XBiotech, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05363891's enrollment target sits among peer trials
243 236th of 2000 higher than 1,764 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06253871 · 243 participants · Phase 1
A Phase 1/1b Study of IAM1363 in HER2 Cancers
- NCT06289491 · 243 participants · NA
A Trial of Hydrus Microstent Versus Goniotomy
- NCT06536296 · 243 participants · NA
The Impact of Music Medicine on Preterm Brain Development and Behavior
- NCT06907615 · 243 participants · Phase 2
A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI